Pharma major Ranbaxy Laboratories, on Monday, said it had restarted production of generic cholesterol-lowering drug Atorvastatin as it looked to resume supplies to the American market.

In November last, the company had recalled Atorvastatin, the generic version of Pfizer’s Lipitor, for select batches in the strengths of 10mg, 20mg and 40mg tablets from the U.S. market due to presence of foreign particles.

Since then, it has been working with the U.S. Food and Drug Administration (USFDA) to implement multiple corrective and preventive actions.

“As part of the first step in initiating the manufacturing process to resume supplies to the U.S. market, we have commenced production of drug substance for our Atorvastatin product,” the company said in a statement.